This site is intended for U.S. healthcare professionals.

Disease Overview

AML is a deadly disease with a high risk of relapse even after achieving a CR or CRi1

Because AML cells may still be present during remission, they have the ability to proliferate and cause relapse2

In 764 patients with AML, 60-85 years of age, relapse rates after induction therapy were as follows3*:

~50 ~50%
relapse within 1 year3,4
~80 ~80%
relapse within 5 years

*A study conducted by the German AML Cooperative Group, published in the Journal of Oncology, assessed OS and remission rates in patients (N=2,776) with treatment-naive AML by age and disease-related variables following various induction therapies. 1,336 patients aged 60-85 were randomized, and ultimately 764 patients received induction therapy and were assessed for OS and remission rates. Induction therapy was defined as either TAD-HAM (combination of cytarabine daunorubicin and thioguanine as the first course, followed by cytarabine and mitoxantrone) or HAM-HAM (cytarabine and mitoxantrone as the first and second course).

Overall, 5-year survival rate for AML is 28.7%5

5-year survival rates are
substantially lower for older
 patients with AML

SEER survival rates by time since diagnosis, 2010-2016.

A goal of continued treatment for AML is extending overall survival6

Continued treatment with ONUREG® can provide a path to extending OS for AML patients in first remission7,8

AML diagnosis
induction therapy
First remission
Consolidation therapy
Receive HSCT7 following induction
Do not receive HSCT7 following induction
50% to 75%
of AML patients
do not receive
Watch and wait8
Continued treatment
with ONUREG®7

In an analysis of the SEER-Medicare 2013-2015 database, 11,142 newly diagnosed adult patients with AML were evaluated and stratified into 2 groups: treatment with chemotherapy (n=4,772) and non-treatment (n=6,370). Within the treatment with chemotherapy group, 55.1% of patients 66 to 70 years of age and 26.6% of patients 71 to 75 years of age went on to receive HSCT.9

While some patients proceed to HSCT, reasons for not receiving transplant may include10-12:

  • Older age
  • Comorbidities
  • Donor unavailability
  • Inadequate social support
  • Patient refusal
  • Worsening performance status
  • Lack of evidence for certain subsets

HSCT, hematopoietic stem cell transplantation.

This site is best viewed in portrait mode on a smartphone or small tablet.